Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus' Zegerid powder for oral suspension has performed well in a clinical trial comparing it with AstraZeneca's Nexium and Tap Pharmaceutical's Prevacid for the treatment of nocturnal acid breakthrough in patients with nocturnal symptoms of gastroesophageal reflux disease.
Subscribe to our email newsletter
Of the 49 patients who completed the study, 61% experienced nocturnal acid breakthrough (NAB) while treated with Zegerid compared to 92% who experienced NAB while being treated with either Nexium or Prevacid.
Data were evaluated after seven continuous days of once-daily dosing. Each study drug was well tolerated, and there were no notable differences between the adverse events reported for the different treatments.
All three drugs in the study are proton pump inhibitors (PPI) that control gastric acidity by reducing the production of gastric acid.
“The results of this clinical study, and our previously published clinical study evaluating Zegerid and Protonix delayed-release capsules in controlling nighttime acidity, are very encouraging for Zegerid,” said Gerald Proehl, president and CEO of Santarus. “We believe that dosing Zegerid powder for oral suspension at bedtime offers physicians an excellent option for treating patients in need of nighttime gastric acid control.”